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A B S T R A C T
Neurodegenerative diseases are among the most common causes of disability worldwide. Although neurode-
generative diseases are heterogeneous in both their clinical features and the underlying physiology, they are all
characterised by progressive loss of specific neuronal populations. Recent experimental evidence suggests that
long non-coding RNAs (lncRNAs) play important roles in the CNS in health and disease. Nuclear Paraspeckle
Assembly Transcript 1 (NEAT1) is an abundant, ubiquitously expressed lncRNA, which forms a scaffold for a
specific RNA granule in the nucleus, or nuclear body, the paraspeckle. Paraspeckles act as molecular hubs for
cellular processes commonly affected by neurodegeneration. Transcriptomic analyses of the diseased human
tissue have revealed altered NEAT1 levels in the CNS in major neurodegenerative disorders as well as in some
disease models. Although it is clear that changes in NEAT1 expression (and in some cases, paraspeckle assembly)
accompany neuronal damage, our understanding of NEAT1 contribution to the disease pathogenesis is still
rudimentary. In this review, we have summarised the available knowledge on NEAT1 involvement in the mo-
lecular processes linked to neurodegeneration and on NEAT1 dysregulation in this type of disease, with a special
focus on amyotrophic lateral sclerosis. The goal of this review is to attract the attention of researchers in the field
of neurodegeneration to NEAT1 and paraspeckles.
1. Introduction
Neurodegenerative diseases (NDDs) are one of the most common
(and growing) causes of disability worldwide. Today, due to the global
extension of lifespan, they represent one of the greatest public health
threats. Dementia of various origins (including Alzheimer's disease),
Parkinson's, Huntington's and motor neuron diseases all belong to this
group, collectively accounting for a significant proportion of age-re-
lated morbidity, including cognitive and motor impairment. NDDs are
heterogeneous in their clinical signs and in the underlying physiology,
however they are all characterised by the progressive loss of specific
neuronal populations [1]. No disease-modifying therapy is currently
available for any of these conditions, with existing drugs being limited
to treating the symptoms rather than the disease process.
Extensive transcriptomic studies fuelled by advanced high-
throughput sequencing technologies and comprehensive bioinformatic
analysis have dramatically expanded our understanding of the in-
credibly complicated yet precisely regulated human transcriptome. It is
now widely accepted that more than 80% of human genome is dyna-
mically transcribed, in a temporally and spatially regulated manner,
and that RNAs not encoding any protein (non-coding RNAs, ncRNAs)
play essential roles in presumably almost every aspect of cellular
biology [2]. In contrast to the ancient short ncRNAs, long ncRNAs
(lncRNAs) appear later in evolution with one third being primate spe-
cific; they are believed to be crucial for the evolution of primate brains
[3]. It is not surprising therefore that lncRNAs, which generally show
unique tissue and cell-type specific expression pattern, are particularly
abundant within the central nervous system (CNS), with at least 40% of
tissue-specific lncRNAs expressed in the brain [4]. lncRNAs are in-
volved in the regulation of a plethora of neurospecific processes, in-
cluding neural plasticity, synaptic transmission, neurogenesis, brain
development and ageing [5,6]. Nuclear Paraspeckle Assembly Tran-
script 1 (NEAT1) is a ubiquitous, highly expressed, nuclear-retained
regulatory lncRNA with important roles in cellular physiology and pa-
thophysiology. In this review, we will discuss the emerging roles for this
lncRNA and the nuclear body it assembles, the paraspeckle, in NDDs,
with a special focus on amyotrophic lateral sclerosis.
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2. NEAT1: two non-coding transcripts with distinct cellular roles
2.1. Long non-coding RNAs: an introduction
The diverse group of ncRNAs includes ribosomal RNA (rRNA),
transfer RNA (tRNA), microRNA (miRNA) and lncRNAs, among others
[7]. ncRNAs have an extremely wide range of size distribution, from
∼20 nucleotides to several kilobases, and lncRNAs are defined as those
longer than 200 nucleotides. lncRNAs are derived from multiple sources
within the genome, including intergenic regions, gene regulatory re-
gions (UTRs, promoters and enhancers) and specific chromosomal re-
gions (telomeres); they can also be derived from the mitochondrial
genome [8–10]. These RNAs are subject to post-transcriptional pro-
cessing and can undergo 5’ capping, polyadenylation, alternative spli-
cing and RNA editing [11,12]. The broad range of functions of lncRNAs
includes roles in transcriptional and epigenetic mechanisms via the
recruitment of transcription factors and chromatin-modifying com-
plexes to specific nuclear and genomic sites; alternative splicing and
other post-transcriptional RNA modifications through the assembly of
nuclear domains containing RNA-processing factors; nuclear-cyto-
plasmic shuttling; and translational control [13,14]. lncRNAs organize
nuclear architecture by concentrating in specific domains close to
transcription sites and forming lncRNA-protein complexes which scaf-
fold protein components of the transcription machinery and modify
chromatin state [15,16]. The abundance of lncRNAs in the nervous
system suggested a strong intrinsic association between the CNS func-
tion and this class of non-coding transcripts, prompting studies into and
rapid discovery of the critical roles lncRNAs play in neurodevelopment,
neuronal plasticity as well as diseases of the nervous system [17,18].
2.2. NEAT1: basic facts
Originally named as Nuclear Enriched Abundant Transcript 1,
which was subsequently changed to Nuclear Paraspeckle Assembly
Transcript 1, NEAT1 is one of the most abundant lncRNAs in the
mammalian nucleus [19]. It is transcribed by RNA polymerase II from a
genetic locus called familial tumour syndrome multiple endocrine neoplasia
(MEN) type I on human chromosome 11 [20], therefore it is also known
under the name “MENepsilon/beta”. The locus gives rise to two isoform
transcripts, 3.7 kb NEAT1_1 (MENepsilon) and 23 kb NEAT1_2 (MEN-
beta), which completely overlap in their 5′-end, through distinct RNA
processing mechanisms. NEAT1_1 is canonically polyadenylated. In
contrast, RNase P recognizes the tRNA-like structure present at the 3′-
end of the primary NEAT1_2 transcript and cleaves it to generate a
triple helix which stabilises NEAT1_2 [21,22]. Mouse Neat1 isoforms
are slightly smaller, 3.1 kb for Neat1_1 and 20 kb for Neat1_2. Unlike
other lncRNAs, which commonly lack sequence conservation, NEAT1 is
relatively conserved across mammalian species, supporting its im-
portant biological function [19]. Indeed, the same structural sub-
domains in NEAT1 could be identified in 40 out of 64 mammalian
species examined, with significant sequence similarity [23]. Moreover,
the main structural features of the NEAT1 locus are also conserved in
marsupials, despite variability of the primary DNA sequence [24].
Mouse Neat1 transcripts have been shown to be very unstable, with
half-lives of ∼30min and ∼60min for Neat1_1 and Neat1_2, respec-
tively [25]. Surprisingly, the same study found that human NEAT1 is
∼7 times more stable than mouse Neat1. The relative instability of
NEAT1 may be critical for rapid cellular response to and subsequent
recovery from stress.
Differential analysis of the two NEAT1 transcripts has proven
challenging for three reasons: i) complete 5′-end overlap of the two
isoforms; ii) presence of adenine stretches in the non-overlapping re-
gion of NEAT1_2, which impedes selective capture of the poly-
adenylated NEAT1_1 using an oligo-d(T) primer; iii) low NEAT1_2 yield
when using conventional RNA extraction methods, due to reduced ex-
tractability of this isoform [26].
Both NEAT1 isoforms are expressed in the majority of cultured cells,
with the exception of embryonic stem cells, which usually acquire
paraspeckles after 4–5 days of differentiation [27]. In vivo, Neat1_1 is
widely expressed, being present at high levels in most organs and tis-
sues of the adult mouse. In contrast, Neat1_2 is only detected in some
cell types in the digestive tract [28]. Both transcripts are also hardly
expressed in the mouse embryo, suggesting a limited role for Neat1 in
mammalian development [28]. Neat1_2 is undetectable in the adult
nervous system [28,29], and human and murine postmitotic neurons
cultured in vitro also have low levels of this isoform [30]. Data on
NEAT1 expression in other cells in the CNS is scarce. Neat1 levels are
low in cultured neuronal/oligodendrocyte progenitors while it becomes
upregulated during differentiation [31].
2.3. The paraspeckle
The most well established function of NEAT1_2 is the assembly of
the nuclear bodies paraspeckles. Multiple NEAT1_2 molecules line up to
construct and maintain the spherical paraspeckle structure [21,32].
Paraspeckles are located in the interchromatin space of mammalian cell
nuclei, usually on the border of splicing speckles [33,34]. NEAT1_2 but
not NEAT1_1 is an essential component of paraspeckles, therefore the
presence of NEAT1_2 is a reliable marker for paraspeckle appearance.
Paraspeckle formation is absolutely dependent on RNA polymerase II
transcription of NEAT1_2 and on the binding of paraspeckle proteins to
this isoform [35]. NEAT1_2 provides a scaffold for> 60 protein com-
ponents and likely multiple RNA components including NEAT1_1
[36–38]. Paraspeckles are currently defined as foci containing both
NEAT1_2 and an essential paraspeckle protein (e.g. SFPQ, NONO) [39].
Electron and super-resolution microscopic analyses revealed the orderly
spatial arrangement of NEAT1_2 and multiple proteins within the
paraspeckle, with a characteristic ‘core-shell’ structure [39–41]. A more
recent study has mapped the minimal paraspeckle-forming region to the
repeat-rich middle part of NEAT1_2 [42]. Computational analysis sug-
gests that the architectural function of NEAT1_2 within paraspeckles is
realised via long-range interactions and requires little structure con-
servation [23].
The majority of protein components of paraspeckles are RNA-
binding proteins [37]. Some of them (SFPQ, NONO, RBM14, hnRNPK)
are known to stabilise NEAT1_2, whereas others regulate the ratio of the
two isoforms (CPSF6, NUDT21) or maintain secondary paraspeckle
structure (FUS, DAZAP1). Another common structural feature of para-
speckle proteins is the presence of low complexity, prion-like domains
enabling phase separation/liquid demixing [42,43], which is required
for the formation of all types of RNA granules [44]. Removal or dis-
ruption of these prion-like domains in core paraspeckle proteins such as
FUS and RBM14 is sufficient to dissipate paraspeckles [43,45].
Although paraspeckle proteome is relatively well-established, less
information is available on the repertoire of RNA components of
paraspeckles. NEAT1_1 is probably the second most abundant RNA
within paraspeckles, after NEAT1_2. It has been estimated that each
paraspeckle contains 6.5 NEAT1_1 and 53 NEAT1_2 molecules [26],
and in stable cell lines, which almost all possess paraspeckles, NEAT1_1
is hardly detected outside these structures. Two structural classes of
RNA species have been reported to be enriched in paraspeckles,
namely, A-to-I hyperedited transcripts including those with inverted
Alu repeats [46]; and miscellaneous of AG-rich RNAs [40]. Most re-
cently, it has been shown that a distinct functional class of transcripts -
mRNAs coding for mitochondrial proteins - are recruited to and re-
tained within paraspeckles [47]. In addition, pri-mRNAs being pro-
cessed by the Microprocessor may constitute a significant proportion of
paraspeckle-anchored RNA [48].
It is believed that NEAT1_2/paraspeckles fulfil a number of func-
tions independent of the presence of NEAT1_1. Among them: i) reg-
ulation of translation via nuclear retention of A-to-I hyperedited RNAs
[27,46,49]; ii) regulation of transcription via sequestration of
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transcription factors, such as SFPQ [50,51]; iii) modulation of pri-
miRNA processing [48]. Since NEAT1_1 is expressed in multiple cell
types devoid of paraspeckles in vivo, including neurons [28], it is clear
that it also has a variety of NEAT1_2/paraspeckle-independent func-
tions. Recent advances in gene editing, which allow generation of cell
lines with isoform-specific knockout [52], should drive forward our
understanding of the functional significance of NEAT1_1.
Paraspeckles are stress-responsive nuclear bodies, in that NEAT1_2
upregulation and the increase in the size/number of paraspeckles ac-
company a number of physiological and pathological stressful condi-
tions, such as differentiation [21] and inhibited proteasome function
[50]. However, we are yet to establish the unifying feature(s) of stresses
triggering the paraspeckle response.
3. NEAT1/paraspeckles regulate cellular pathways commonly
affected in neurodegenerative diseases
Neurological disorders are defined as diseases of the central and
peripheral nervous systems, and included within this category are age-
related NDDs [53]. NDDs represent a large group of devastating, re-
lentlessly progressive conditions with diverse clinical and pathological
expressions, which are typically characterised by preferential loss of
certain subsets of neurons in specific anatomical regions [54,55].
Among the hundreds of different NDDs, there are several common ones,
including Alzheimer's disease (AD), Parkinson's disease (PD), amyo-
trophic lateral sclerosis (ALS), frontotemporal dementia (FTD) and
Huntington's disease (HD), which collectively affect an estimated 50
million people globally. There is often little family history, and even
among cases with familial aggregation, their genetic landscape can be
highly heterogeneous. Polygenic/multifactorial nature of these condi-
tions presents an obstacle to selection of specific molecular pathways
for developing targeted therapeutics applicable across different disease
subtypes.
Experimental evidence accumulated so far suggests that NEAT1
fine-tunes the function of multiple neurodegeneration-associated
pathways, including critical ones, such as inflammation and neuronal
apoptosis. Moreover, some of these pathways, e.g. mitochondrial sig-
naling and miRNA biogenesis, are specifically regulated by NEAT1_2/
paraspeckles. Below, we have summarised current knowledge of the
role of NEAT1/paraspeckles in each of these pathways.
Apoptosis and the p53 pathway. Programmed cell death is the pri-
mary cause of neuron loss in NDDs, and both apoptosis and necroptosis
contribute to this pathological process [56,57]. p53 is an established
mediator of apoptosis in response to major insults in neurons [58].
Levels of p53 are generally increased in the affected CNS regions in
NDDs, both in patients and in respective in vivo disease models [59]. In
vivo studies confirmed that p53 acts as a positive regulator of disease
pathogenesis in mouse models of NDDs [60,61].
Experimental data support the anti-apoptotic properties of NEAT1
and/or paraspeckles. Neat1 ablation renders mouse fibroblasts sensitive
to cell death induced by proteasome inhibition [50]. Similarly, acute
NEAT1 downregulation in human cells potentiates dsRNA cytotoxicity
[30]. Furthermore, NEAT1 inhibits apoptosis under conditions of low
oxygen and/or glucose [62,63]. Human and mouse NEAT1 are posi-
tively regulated by p53, and a p53 binding site on Neat1 promotor
containing a consensus p53-binding element has been identified
[64,65]. So far, studies of the interplay between NEAT1 and p53 have
been carried out mainly in the context of cancer. Precise molecular
mechanisms, including neurospecific ones, which underlie the co-op-
eration of NEAT1 with the p53 pathway and other apoptotic factors/
pathways still remain to be elucidated.
Proteotoxicity. Uncontrollable protein aggregation and inclusion
formation is undoubtedly a hallmark of all NDDs [66]. Disease-asso-
ciated proteins typically become misfolded and form amyloid or non-
amyloid deposits in the affected CNS regions. Failure of the three main
protein quality control systems, namely the molecular chaperone
network, the ubiquitin-proteasome system and the autophagosome-ly-
sosome pathway, will lead to proteostasis collapse in neurons and their
rapid demise [67–70].
Heat shock response is one of the main pro-survival pathways acting
to maintain cellular protein homeostasis. Heat-shock proteins (HSPs)
controlled by heat shock transcription factor 1 (HSF1) are molecular
chaperones exerting anti-aggregational activity. Attenuated function of
HSPs may be contributory in various NDDs [71], and HSF1 is proposed
as a therapeutic target in these conditions [72]. Recently, a heat shock
element (HSE) has been identified within NEAT1 promoter region, and
HSF1-inducing stimuli have been shown to upregulate NEAT1 and en-
hance paraspeckle formation [73].
Proteasome inhibition is a well-established trigger of NEAT1 upre-
gulation and paraspeckle hyper-assembly. Both NEAT1 isoforms are
accumulated in cells treated with commonly used proteasome inhibitors
bortezomib or MG132 [50]. Cells with enlarged paraspeckles may
present with up to 50% nucleoplasmic depletion of paraspeckle pro-
teins, many of which are transcription factors. Thus paraspeckles are
likely to heavily contribute to the regulation of gene expression under
these conditions. However, how exactly disrupted proteasome de-
gradation signals to NEAT1 and paraspeckles is yet to be determined.
One possible mechanism is that supressed proteasomal degradation of
HSF1 drives the build-up of activated HSF1, which in turn augments
NEAT1 synthesis [74].
Inflammatory response. Neuroinflammation, defined as activation
and/or proliferation of resident immune cells in the CNS, is one of the
central disease mechanisms in NDDs, as reviewed extensively elsewhere
[75]. Genetic evidence also supports the major contribution of in-
flammatory pathways in the disease process. For example, genome-
wide association studies (GWAS) found strong links between the in-
flammatory pathway genes and the risk of AD. As of today, over 20
genes bearing risk alleles have been identified in this pathway, and
many of them are microglia-specific [76]. Genetic variants in TREM2, a
gene which in the CNS is expressed only by microglia, have been as-
sociated with AD, FTD and PD [77].
NEAT1 involvement in the cellular response to pathogens is well
established. In fact, Neat1_1 was first discovered as a virus-inducible
non-coding RNA (VINC): a transcript undetectable in uninfected mouse
brains was produced in response to Japanese encephalitis virus or
Rabies virus infection [78]. NEAT1 roles in antiviral response, in-
cluding via paraspeckles, have been confirmed in subsequent studies
[51,79]. In virus-infected or dsRNA-stimulated HeLa cells, upregulated
NEAT1 and enlarged paraspeckles act to sequester SFPQ away from
promoters of cytokine and chemokine genes, such as IL8 or CCL5, which
are repressed by SFPQ in the basal state. Importantly, the function of
paraspeckles in this process was addressed using NEAT1_2 over-
expression, confirming that the majority of the observed effects are
mediated by paraspeckles. Subsequently, we showed that accumulation
of endogenous dsRNA also promotes NEAT1 synthesis and paraspeckle
assembly in human stable cell lines [30]. Another facet of NEAT1
function in the innate immunity is the regulation of cellular response to
abnormal DNA species. Upon dsDNA exposure, NEAT1 binds to
HEXIM1 protein leading to remodelling of a specific nuclear complex
and activation of the cGAS-STING-IRF3 pathway and interferon sig-
nalling [80]. In other studies, NEAT1 was also found to positively
regulate the expression of a group of cytokines and chemokines, in-
cluding IL6 and CXCL10, in human monocytic cells in response to
bacterial stimulation [81,82]. However, data from another study in-
dicate that NEAT1 represses IL-1β and TNF-α production in the im-
mortalized mouse neuronal line HT22 [63], pointing to possible cell
type and/or species specificity of NEAT1 effects. While it is clear that
NEAT1 upregulation is generally associated with positive regulation of
immune signalling, currently we lack critical knowledge of the differ-
ential NEAT1 expression in the immune cells within the CNS. This in-
formation is required to instruct further studies of NEAT1 contribution
to neuroinflammatory responses in vitro and in vivo.
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Mitochondrial signalling. Defects in mitochondrial function accom-
pany almost all NDDs [83]. Because of high energy demand, neurons
are exceptionally sensitive to mitochondrial dysfunction. PD-causative
mutations have been identified in the genes encoding proteins involved
in mitochondrial quality control, parkin and PINK1 [84].
Recently, an unexpectedly strong mitochondria-paraspeckle cross-
talk has been reported [47]. A large group of nuclear encoded genes
regulating mitochondrial functions have been found to control NEAT1
levels and paraspeckle abundance via the transcription factor ATF2.
Moreover, this effect is reciprocal, because elimination of paraspeckles
is sufficient to cause mitochondrial abnormalities, including reduced
respiration and ATP production as well as defective mitochondrial fis-
sion [47]. One can speculate that the observed effects of mitochondrial
stress on paraspeckles could be at least in part mediated by the in-
duction of immune response by damaged mitochondria [85]. Indeed,
mitochondrial defects may lead to mtDNA instability, its escape to the
cytosol and activation of cGAS-STING-IRF3 signalling responsive to
foreign DNA, as described above.
Neurospecific pathways. NEAT1 function has been linked to neuronal
excitability and axonal growth/maintenance. Abnormal excitability of
the affected neuronal populations has been reported in ALS, AD and PD
and likely represents an important disease mechanism common for
many NDDs [86]. Hyperexcitability of upper and lower motor neurons
has long been considered as one of the early disease signs in ALS
[87,88].
NEAT1 is an activity-dependent transcript, as can be inferred from
its higher expression in the “active”, high-spiking regions of the human
brain and its responsiveness to depolarisation [89,90]. Moreover, since
knockdown of NEAT1 in cultured human neurons leads to a significant
increase in the expression of ion channel components, NEAT1 may
control the transcription of genes encoding this class of proteins and act
as a negative regulator of neuronal excitability [89]. The same study
also reports that NEAT1 can directly bind to different potassium
channel-interacting proteins, for example KCNAB2, important in redu-
cing the excitability of neurons. NEAT1 is acutely downregulated in
response to depolarisation, which is proposed to aid the translocation of
KCNAB2 from nucleus to cytoplasm. In the cytoplasm, KCNAB2 would
modulate the excitatory response through interacting with the mem-
brane channels [89]. Notably, these effects are attributable to NEAT1_1
function, because this isoform is almost solely expressed in cultured
postmitotic neurons used in the above experiments.
Unexpectedly, transcriptomic analysis of non-neuronal cells lacking
Neat1 expression, Neat1 knockout fibroblasts, revealed that the genes
most downregulated in these cells are involved in the nervous system
development and function as well as axon guidance [64]. Indeed, stu-
dies in primary neuronal cultures showed that Neat1 knockdown de-
creases axonal growth, whereas Neat1 overexpression has the opposite
effect [63].
miRNA biogenesis, chromatin remodelling and circadian rhythms. A
number of other cellular pathways, whose dysfunction is less specific
yet also relevant to NDDs, are modulated by NEAT1/paraspeckles.
Gene silencing mediated by miRNAs is the major post-transcrip-
tional gene repression mechanism. Altered miRNA levels have been
detected in the CNS in multiple NDDs, including AD, PD, HD, ALS and
FTD [18,91]. The core Microprocessor component Drosha has been
found to be abnormally aggregated in a subtype of ALS caused by repeat
expansions in the C9ORF72 gene [92]. Moreover, genetic disruption of
miRNA biogenesis in the mammalian nervous system is sufficient to
cause a neurodegenerative phenotype. For example, ablation of the
endoribonuclease Dicer, which processes miRNA precursors into ma-
ture miRNAs, in the adult mouse brain leads to hyperphosphorylation
of tau protein and neuronal loss in the hippocampus, the two char-
acteristic features of AD [93]. Furthermore, motor neuron specific
knockout of Dicer results in an ALS-like phenotype in mice [94]. A
recent study has revealed that NEAT1, as part of paraspeckles, functions
to facilitate pri-miRNA processing [48]. This activity of paraspeckles is
realised via bringing together multiple components of the nuclear
miRNA machinery and scaffolding the Microprocessor complex.
NEAT1_2 contains a pseudo pri-miRNA in its 3’ end, which attracts the
Microprocessor and increases its local concentration. The role for
NEAT1_1 in this process is less clear, however, it may potentiate
NEAT1_2 function. A number of NEAT1-binding proteins, namely FUS,
TDP-43, SFPQ and EWS, have been reported to modulate miRNA bio-
genesis [95–98].
NDDs are generally characterised by a misbalance between the ac-
tivity of histone acetyltransferases (HATs) and histone deacetylases
(HDACs) and resulting histone hypoacetylation and repressed chro-
matin state [99]. Abnormal signalling of CREB-binding protein (CBP), a
HAT co-activator, is typical for AD, HD and ALS [100]. According to
CHART-Seq results, NEAT1 binds active chromatin sites, whereas sti-
mulation or inhibition of transcription alters the pattern of NEAT1
binding [101]. Furthermore, chromatin isolation by RNA purification
(ChIRP) analysis showed that NEAT1 is recruited to gene promoters
thereby supporting active chromatin state; it can do so via direct in-
teraction with histone H3 [102]. NEAT1 might serve to recruit chro-
matin-modifying machinery and thus favour a chromatin landscape for
active transcription. It should be noted however that both of the above
studies did not distinguish between the two NEAT1 isoforms.
Disturbances of the physiological circadian rhythms, including
sleep/awake cycle, core body temperature fluctuations and hormone
release are among the earliest symptoms of NDDs [103]. Intriguingly,
NEAT1 displays circadian expression patterns, and NEAT1/para-
speckles post-transcriptionally control the daily fluctuations in cellular
protein levels through retaining inverted Alu repeat containing mRNAs
in the nucleus [104].
In conclusion, since NEAT1_2 is virtually undetectable in the
healthy CNS, currently it is of pivotal importance to determine the
differential role of NEAT1_1 in the above pathways.
4. NEAT1/paraspeckles are dysregulated in neurodegenerative
diseases: evidence from human tissue and disease models
Studies in human post-mortem tissue and experiments in in vitro and
in vivo disease models have demonstrated that a neurodegenerative
process is generally accompanied by altered NEAT1 levels. Below, we
have summarised published information on NEAT1 expression in the
affected parts of the CNS in patients and in rodent models of disease (a
brief summary is also given in Table 1). The majority of studies report
the expression levels of NEAT1 gene without accounting for the ex-
istence of the two isoforms with distinct functions. Thus, hereafter, we
will refer to NEAT1 gene products as ‘NEAT1‘, clearly stating if the
effects are isoform-specific, where and when such data are available.
4.1. Amyotrophic lateral sclerosis (ALS) and frontotemporal lobar
degeneration (FTD)
ALS is a fatal adult-onset progressive neuromuscular disease af-
fecting motor neurons in the spinal cord and motor cortex. Up to 90% of
ALS cases are sporadic (sALS), and the remaining 10% have a familial
history (familial ALS, fALS); so far, mutations in more> 25 genes have
been found to cause fALS and sALS [105,106]. FTD is characterised by
frontal lobe pathology and hence decline of cognitive function. There is
a significant genetic overlap between ALS and FTD; in addition, the two
conditions can co-exist in the same individual, which has led to them
being combined into one disease spectrum [107]. Significant propor-
tion of ALS and FTD cases are caused by mutations in genes encoding
RNA-binding proteins (RBPs) and/or involve functional deregulation of
RBPs, which points to abnormal RNA metabolism as a common pa-
thogenetic mechanism [108].
The first study to implicate NEAT1 in ALS pathogenesis reported
enhanced paraspeckle formation in spinal motor neurons in a small
cohort of sALS patients [109]. In view of the fact that NEAT1_2
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expression is low in the adult nervous system, detection of paraspeckles
in motor neurons was somewhat unexpected. Recently, we have con-
firmed that paraspeckle hyper-assembly is typical for motor neurons in
ALS in a different cohort of sALS cases [30]. Furthermore, we also
showed that this phenomenon is not restricted to sALS but is also ob-
served in fALS cases caused by the C9ORF72 and TARDBP gene muta-
tions. Mechanistically, augmented paraspeckle formation in ALS can be
caused, at least in part, by nuclear depletion of TDP-43, the protein
most commonly dysregulated in ALS (aggregated and lost from the
nucleus in 95% of sALS cases) [110]. Indeed, TDP-43 binds NEAT1
[111,112], and its downregulation stimulates NEAT1_2 accumulation
and paraspeckle assembly in cultured cells [30].
Genetic evidence also supports an important role for NEAT1/para-
speckles in ALS pathogenesis. Indeed, out of ∼25 proteins genetically
associated with ALS/FTD, eight proteins are paraspeckle components,
namely FUS, TDP-43, EWS, TAF15, SFPQ, MATR3, CREST and hnRNP
A1, and some of them regulate NEAT1 levels and paraspeckle assembly
(Table 2). In addition to the direct negative effect of a mutant protein
on NEAT1/paraspeckles, its pathological aggregates can sequester other
paraspeckle components. For example, inclusions of FUS protein in ALS
caused by FUS gene mutations capture and retain proteins which reg-
ulate NEAT1 levels, such as NONO [45], whereas nuclear aggregates
formed by mutant CREST can sequester FUS [113]. Furthermore, ab-
normal nuclear RNA foci formed by the ALS-causative expanded
C9ORF72 repeats also sequester paraspeckle proteins hnRNPK, TDP-43
and EWS [114]. Therefore, abnormal levels, distribution, stability and
interactions typical for mutant versions of these ALS-linked proteins
may disrupt protective NEAT1/paraspeckle mediated signalling in ALS
(Fig. 1).
NEAT1 is one of the most upregulated transcripts in the brains of
patients affected by FTD [111]. It should be noted however that this
study measured TDP-43 binding to NEAT1 rather than absolute NEAT1
levels. Another study detected NEAT1 upregulation in the brain in a
small cohort of FTD patients using qRT-PCR [115]. Upregulation of
NEAT1_2 and paraspeckle formation is not typical for frontal cortex
neurons in FTD (our unpublished observations). Studies into differences
in NEAT1_2 regulation in motor and cortical neurons may shed light on
the reasons behind selective vulnerability of neuronal populations in
ALS and FTD.
4.2. Huntington's disease (HD)
HD is a hereditary NDD, of which 90% are familial cases caused by
CAG trinucleotide repeat expansion in the HTT gene. HTT encodes a
ubiquitously expressed protein with largely unknown functions. HD
selectively affects GABAergic medium spiny neurons in the caudate
nucleus and putamen, causing a series of symptoms including chorea,
cognitive dysfunction and psychiatric disturbances. Healthy individuals
have less than 36 CAG-repeats in HTT alleles, while affected individuals
possess longer CAG repeats, with the length positively correlated with
the severity of the phenotype [116]. Mutant huntingtin may cause
neurodegeneration via a combination of transcriptional dysregulation,
impaired clearance and toxicity of misfolded proteins, mitochondrial
dysfunction, and oxidative stress [117].
Re-analysis of microarray data for the caudate from 44 HD cases and
36 controls [118] showed significant NEAT1 upregulation in the patient
cohort [119]. Microarray analysis of another cohort of HD patients
further confirmed elevated NEAT1 levels in the caudate of affected
individuals [120]. RNA-Seq analysis of prefrontal cortex from 20 HD
and 49 control individuals also found moderate, ∼20% upregulation of
NEAT1 in HD [121]. A recent study, specifically focused on NEAT1_2,
detected 3-fold increase of this isoform in the brain of HD patients by
qRT-PCR [122]. Consistently, NEAT1 is overexpressed in the brains of
R6/2 transgenic mice, a well-established HD model [120,123]. In cell
models of HD, overexpressing mutant huntingtin, exogenous NEAT1_1
protected cells against H2O2-induced toxicity [120], whereas NEAT1_2
knockdown decreased cell survival [122].
4.3. Parkinson's disease (PD)
PD is characterised by a distinctive set of movement disorders in-
cluding bradykinesia, tremor, rigidity and postural instability; psy-
chiatric symptoms are present in a subset of patients. PD primarily af-
fects the nigrostriatal dopaminergic system. The affected neurons
develop Lewy bodies – neuronal inclusions composed of α-synuclein;
this protein is also mutated in several forms of PD [124]. Other genes
Fig. 1. NEAT1/paraspeckles in ALS: a working model.
Left panel. Under basal conditions, levels of NEAT1_2 in motor neurons are low and so are the paraspeckle numbers. Paraspeckle assembly might also be transient (“on
demand”).
Middle panel. During development of pathological changes typical for ALS, paraspeckle hyper-assembly is triggered by internal and external insults, such as TDP-43
loss of function (LoF), proteostasis collapse and immune response. Subsequent signalling events would enable protective neuronal response to stress and delay
neuronal degeneration.
Right panel. In ALS cases with an essential/important paraspeckle protein affected by a mutation (see Table 2), its mutant isoform might negatively impact on
protective paraspeckle hyper-assembly. This can be realised through: i) failure to upregulate NEAT1_2 (e.g. if proteins regulating NEAT1_2 levels, such as SFPQ and
hnRNP K, are mutated or sequestered into abnormal inclusions/RNA foci); ii) attenuated assembly of paraspeckles or assembly of dysfunctional paraspeckles (e.g. if a
structural paraspeckle protein, such as FUS, is mutated); iii) persistence of paraspeckles (e.g. if a mutation confers abnormal stability). Defective paraspeckle response
may expedite the development of molecular pathology and accelerate disease onset and progression. A mutant protein is marked by a red star.
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associated with PD include PINK1, DJ-1, LRRK2, and Parkin [125]. Si-
milar to HD, mitochondrial damage, oxidative stress, excitotoxicity,
protein misfolding and aggregation, and impaired protein clearance
have all been implicated in PD [126].
Meta-analysis of a publicly available microarray dataset for sub-
stantia nigra (151 PD patients and 130 healthy controls) showed ∼1.5
upregulation of NEAT1 in PD patients [127]. Two in vivo studies report
upregulation of NEAT1 in the midbrain of an MPTP mouse model of PD
[128,129]. Contrary to the proposed protective effect of NEAT1 in other
NDDs, in vitro and in vivo studies suggested that NEAT1 upregulation
might play a detrimental role in PD. Neat1 knockdown prior to the
MPTP injection in mice significantly increased survival of dopaminergic
neurons [128]. NEAT1 knockdown also protected MPP + treated SH-
SY5Y neuroblastoma cells from apoptosis [128,129].
4.4. Alzheimer's disease (AD)
AD is the most common NDD presenting with a progressive loss of
cortical and hippocampal neurons and irreversible decline of cognitive
and behavioural functions; 95% cases are sporadic [130,131]. AD is
characterised by two distinctive pathological hallmarks: accumulation
of extracellular neuritic plaques composed primarily of Aβ1−42, a
cleavage product of the amyloid precursor protein (APP), and in-
tracellular collections of neurofibrillary tangles composed of hyper-
phosphorylated species of tau protein [55]. The three main causative
genes (APP, PSEN1, and PSEN2) and one common genetic risk factor
(APOEε4 allele) have been identified. Large-scale GWAS studies found
multiple additional risk loci for late-onset AD, with the associated genes
mapping to the three principal pathways: cholesterol and lipid meta-
bolism; immune system and inflammatory response; and endosomal
vesicle cycling [132].
Microarray analysis of 87 AD and 74 control subjects showed
NEAT1 overexpression across five different brain regions of AD pa-
tients, namely entorhinal cortex, hippocampus, middle temporal gyrus,
posterior cingulate cortex and the superior frontal gyrus [133]. Statis-
tically significant, ∼2.5-fold upregulation of NEAT1 in the hippo-
campus has been found in a small cohort of late-onset AD patients using
RNA-Seq [134]. Another study also reported a 3-fold increase in NEAT1
in the temporal cortex and hippocampus of AD patients as measured by
qRT-PCR [135].
4.5. Other diseases characterised by neurodegenerative process
A number of conditions outside the classical age-related NDD group
are also characterised by progressive neurodegeneration and associated
cognitive and physical impairement. Among them, NEAT1 dysregula-
tion has been detected in epilepsy, traumatic brain injury (TBI) and
drug addiction. Chromosomal 11q13 region containing NEAT1 locus
was previously implicated in idiopathic seizures [136]. NEAT1 was
found to be upregulated in the cerebral cortex in a small cohort of
patients with temporal lobe epilepsy, specifically in high activity as
compared to low activity regions [89,90]. However, in pilocarpine or
kainic acid induced rat epilepsy models, Neat1 was transiently down-
regulated [89]. Authors propose that chronic upregulation of NEAT1 in
neurons and inability to reduce its levels on demand may cause in-
sensitivity to physiological activity rhythms and result in abnormal
neuronal excitability. In another study, also in a mouse model of kainic
acid induced seizures, the two Neat1 isoforms exhibited different post-
seizure dynamics in the hippocampus, with acute Neat1_1 upregulation
and delayed but prolonged Neat1_2 upregulation [29]. In this model,
Neat1_2 was likely elevated specifically in neurons, whose density is
very high in the hippocampus. Since Neat1_2 is undetectable in the
brain at the basal state, its induction by activity changes, with a tem-
poral pattern distinct from that of Neat1_1, is very intriguing and
warrants further, in-depth studies.
TBI is characterised by neuronal loss and also recognised as a risk
factor for NDDs [137]. NEAT1 levels in the cerebral cortex increase
significantly following TBI, being nearly 3-fold higher one day after the
injury [138]. Interestingly, NEAT1 has also been found upregulated in
the brain of heroin users [139].
5. Conclusions and therapeutic implications
The hypothesis that NEAT1 and paraspeckles have important pa-
thogenetic connections to age-related NDDs is gaining more credence.
Yet we are just beginning to paint the picture of NEAT1 distribution,
regulation and functions in the nervous system and of how they could
be affected in NDDs. Carefully planned in vitro and in vivo experiments
are still required to unambiguously establish whether, and if so, under
which conditions NEAT1 isoforms may be neuroprotective. To begin to
appreciate the spectrum of cellular effects of NEAT1 in NDDs, we need
to elucidate: 1) cell-specific differences in NEAT1 expression in the CNS
and whether this expression pattern is recapitulated in cultured cells; 2)
NEAT1 roles in the normal nervous system at molecular, cellular, tissue
and behavioural levels; 3) molecular mechanisms and temporal dy-
namics of NEAT1 regulation in neuronal populations affected in dif-
ferent NDDs; 4) differential roles for NEAT1_1 and NEAT1_2 in the
protective neuronal responses. Although no gross neuropathological
changes have been reported in the Neat1 knockout mouse model [28],
thorough analysis of the CNS function of these mice complemented
with studies of isolated primary neurons should provide important clues
to the neurospecific-roles of NEAT1. Needless to say, we also need to
carry out meta-analyses of available transcriptomic data from patients
with different NDDs with a focus on lncRNAs.
Chemical modulation of NEAT1 expression as well as the use of
antisense oligonucleotides (ASOs) to switch between the isoforms may
become viable therapeutic approaches for this aetiologically diverse
group of diseases. ASOs are currently being explored as possible ther-
apeutic options for monogenic NDDs [140]. As a word of caution
however, ASOs may affect NEAT1 and paraspeckles in an unconven-
tional way. Indeed, phosphorothioate(PS)-modified ASOs form intra-
nuclear structures which recruit paraspeckle proteins, ultimately
leading to rapid NEAT1 decay [141]. Furthermore, the commonly used
2′-Fluoro modification of PS-ASOs have been found to cause degrada-
tion of the NEAT1-stabilising proteins NONO and SFPQ and to down-
regulate NEAT1 [142]. Therefore, further studies are needed to rule out
possible impact of ASOs on NEAT1 levels.
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